The trial will allocate participants 1:1:1:1 to receive oral AEF0217 at three dose levels or placebo for 24 weeks. Credit: SmartPhotoLab / Shutterstock.com. Aelis Farma has launched its Phase IIb ...
Parkinson’s disease is a progressive neurological disorder, which is caused by the degeneration of dopamine-producing neurons in the brain. Credit: Naeblys via Shutterstock.com. As Parkinson’s disease ...
Zegfrovy is described as an irreversible EGFR inhibitor targeting a range of EGFR mutations with wild-type selectivity. Credit: Arif biswas / Shutterstock.com. Dizal’s Phase III WU-KONG28 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results